Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, small 30-patient, one-year confirmatory clinical trial in Japanese patients that compares NeoCart to microfracture

Next Previous
X
Search
Trial Profile

A Phase 3, small 30-patient, one-year confirmatory clinical trial in Japanese patients that compares NeoCart to microfracture

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous chondrocyte implantation (Primary)
  • Indications Cartilage disorders; Knee injuries
  • Focus Registrational; Therapeutic Use
  • Sponsors Histogenics Corporation; Ocugen

    • Most Recent Events

    • 21 Aug 2023 According to an Ocugen media release, the company plans to initiate the Phase 3 trial in the second half of 2024.
    • 28 Feb 2023 According to an Ocugen media release, company received concurrence from the FDA on this confirmatory Phase 3 clinical trial design and plans to initiate this trial in the first half of 2024.
    • 16 Dec 2022 According to an Ocugen media release, the company plans to file an Investigational New Drug amendment to initiate of this clinical trial in late 2023/early 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top